SynthesisClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2026
The Affordable Care Act Improves Access, Survival, and Racial Disparities of Patients With Liver Disease: A Systematic Review.
Synthesis in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND &
aimsGiven the evolving epidemiology of liver disease, escalating healthcare costs, and persistent racial health disparities, evaluating the Affordable Care Act (ACA)-the most substantial U.S. healthcare reform to date-is critical for informing future policy. We conducted a systematic review to assess the impact of the ACA and its Medicaid Expansion (ME) provision on access to care, survival, and racial and ethnic disparities among patients with chronic liver disease (CLD).
methodsWe reviewed studies published between 2010 and 2025 that included adults with CLD and evaluated ACA/ME effects on access to services, survival or mortality, or disparities in outcomes. Studies compared ME and non-Medicaid Expansion (NME) states during pre- and post-ACA periods. Risk of bias was assessed using a validated tool.
resultsTwenty-seven studies met inclusion criteria across 4 clinical categories: hepatitis C virus (n = 4), liver transplantation (n = 10), hepatocellular carcinoma (n = 9), and cirrhosis or CLD (n = 5). Twenty-three studies reported improved outcomes associated with ACA/ME. Difference-in-difference analyses showed liver transplantation listing increased by 1.8% to 6.0% in ME vs NME states; early-stage hepatocellular carcinoma diagnosis increased by 5.4%, and cirrhosis-related mortality rose more slowly in ME states (0.5-1.0 per 100,000 vs 1.4-10.4 per 100,000). Most studies were at low-to-moderate risk of bias and used causal inference methods.
conclusionsThe ACA, particularly ME, improved access, survival, and equity among Medicaid-eligible adults with CLD. Individuals in NME states would likely benefit from expansion, and future liver health policy should consider these findings to reduce disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.